跳到正文
原文
Endpoints News 生物医药· Reynald Castaneda·· 4 天前AI 评分60

CG Oncology 的膀胱癌治疗在 III 期试验中超出预期

CG Oncology's bladder cancer treatment beats expectations in Phase 3

AI 导读

CG Oncology 的免疫治疗在 III 期试验中对某些非肌肉浸润膀胱癌患者表现出色,可能显著扩大该产品的市场。

正文

CG On­col­o­gy said its on­colyt­ic im­munother­a­py suc­ceed­ed in a late-stage tri­al in cer­tain pa­tients with non-mus­cle in­va­sive blad­der can­cer, po­ten­tial­ly ex­pand­ing the as­set’s mar­ket sig­nif­i­cant­ly.

…

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news